Melatonina Mylan

Melatonin, the active ingredient in Melatonina Mylan, is a melatonin receptor agonist presented as an oral formulation for oral use. It is used to help regulate sleep‑wake cycles in adults experiencing insomnia or jet lag. GNH USA supplies Melatonina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melatonina Mylan is a melatonin receptor agonist that acts on the circadian‑regulation pathway to improve sleep quality. - Insomnia: helps reduce time to fall asleep and increase total sleep duration. - Jet lag: assists in realigning the internal clock after rapid time‑zone travel. - Circadian rhythm disturbances: supports synchronization of the sleep‑wake cycle in shift‑work or delayed‑sleep‑phase situations.

Melatonina Mylan is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Drowsiness or daytime sleepiness - Headache - Dizziness - Nausea or mild gastrointestinal discomfort - Vivid dreams or altered dream patterns - Mild fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, itching, or angioedema - Severe dizziness or vertigo - Mood changes including depression or irritability - Hallucinations or vivid nightmares (rare) - Significant blood pressure changes (rare)

When considering melatonin therapy, several safety points should be observed. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown safety; weigh potential benefits against risks. - Concomitant CNS depressants: may increase sedation, monitor alertness. - Autoimmune disorders: discuss with physician as melatonin can modulate immune function. - Elderly patients: start with the lowest effective dose due to increased sensitivity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Melatonin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Immunosuppressants (e.g., cyclosporine): may reduce immunosuppressive efficacy. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): can raise melatonin plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Antihypertensives: possible enhancement of blood‑pressure‑lowering effect. - Oral contraceptives: may increase melatonin concentrations, requiring observation.